This study is testing an FDA-approved drug called CYTALUX (pafolacianine) to see if it can help surgeons find cancer cells during operations for certain cancers. CYTALUX attaches to cancer cells and "lights up" when viewed with a special camera, making it easier to see. The study wants to find out if using CYTALUX with this special imaging can improve how doctors detect cancerous tissue in adults undergoing surgery for gastrointestinal (stomach and intestines), foregut (upper digestive tract), pancreatic, hepatobiliary (liver and bile ducts), esophageal (food pipe), or gynecologic (female reproductive organs) cancers. You might be able to join if you are 18 or older and are having surgery for one of these cancers. The study is considered successful if a good number of patients have cancer spots light up that weren't seen before.

Study design

This is an interventional study planning to enroll 50 participants. It is a single-dose pilot study, meaning participants will receive one dose of the study drug.

What's involved

You will receive a single intravenous (IV) injection of CYTALUX (pafolacianine) between 1 and 24 hours before your surgery. The study will then observe if any cancer tissue lights up during your operation.

Compensation

Not stated in the trial record.

Follow-up

The main observation for this study happens on Day 1, during your surgery, to see if cancer tissue is detected.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.